140 related articles for article (PubMed ID: 20960028)
1. Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.
Okamoto I; Shimizu T; Miyazaki M; Tsurutani J; Ichikawa Y; Terashima M; Takeda M; Fumita S; Ohki E; Kimura N; Hashimoto J; Nakagawa K
Invest New Drugs; 2012 Apr; 30(2):639-46. PubMed ID: 20960028
[TBL] [Abstract][Full Text] [Related]
2. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
Chow LQ; Blais N; Jonker DJ; Laurie SA; Diab SG; Canil C; McWilliam M; Thall A; Ruiz-Garcia A; Zhang K; Tye L; Chao RC; Camidge DR
Cancer Chemother Pharmacol; 2012 Mar; 69(3):709-22. PubMed ID: 21989766
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
Blais N; Camidge DR; Jonker DJ; Soulières D; Laurie SA; Diab SG; Ruiz-Garcia A; Thall A; Zhang K; Chao RC; Chow LQ
Invest New Drugs; 2013 Dec; 31(6):1487-98. PubMed ID: 23963796
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
Camidge DR; Blais N; Jonker DJ; Soulières D; Doebele RC; Ruiz-Garcia A; Thall A; Zhang K; Laurie SA; Chao RC; Chow LQ
Cancer Chemother Pharmacol; 2013 Feb; 71(2):307-19. PubMed ID: 23108697
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Sweeney CJ; Chiorean EG; Verschraegen CF; Lee FC; Jones S; Royce M; Tye L; Liau KF; Bello A; Chao R; Burris HA
J Clin Oncol; 2010 Oct; 28(29):4513-20. PubMed ID: 20837944
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.
Boku N; Muro K; Machida N; Hashigaki S; Kimura N; Suzuki M; Lechuga M; Miyata Y
Invest New Drugs; 2014 Apr; 32(2):261-70. PubMed ID: 23665950
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
Leong S; Eckhardt SG; Chan E; Messersmith WA; Spratlin J; Camidge DR; Diab S; Khosravan R; Lin X; Chow Maneval E; Lockhart AC
Cancer Chemother Pharmacol; 2012 Jul; 70(1):65-74. PubMed ID: 22623210
[TBL] [Abstract][Full Text] [Related]
9. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
Infante JR; Novello S; Ma WW; Dy GK; Bendell JC; Huff A; Wang Q; Suttle AB; Allen R; Xu CF; Ottesen LH; Burris HA; Adjei AA
Invest New Drugs; 2013 Aug; 31(4):927-36. PubMed ID: 23179337
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
Heath EI; Blumenschein GR; Cohen RB; Lorusso PM; Loconte NK; Kim ST; Ruiz-Garcia A; Chao RC; Wilding G
Cancer Chemother Pharmacol; 2011 Sep; 68(3):703-12. PubMed ID: 21140147
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
Michaelson MD; Zhu AX; Ryan DP; McDermott DF; Shapiro GI; Tye L; Chen I; Stephenson P; Patyna S; Ruiz-Garcia A; Schwarzberg AB
Br J Cancer; 2013 Apr; 108(7):1393-401. PubMed ID: 23511559
[TBL] [Abstract][Full Text] [Related]
12. A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.
Chu QS; Sangha R; Hotte SJ; Sergenson G; Schnell D; Chand VK; Hirte HW
Invest New Drugs; 2014 Dec; 32(6):1226-35. PubMed ID: 25037863
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
Robert F; Sandler A; Schiller JH; Liu G; Harper K; Verkh L; Huang X; Ilagan J; Tye L; Chao R; Traynor AM
Cancer Chemother Pharmacol; 2010 Sep; 66(4):669-80. PubMed ID: 20043166
[TBL] [Abstract][Full Text] [Related]
14. A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
Boven E; Massard C; Armand JP; Tillier C; Hartog V; Brega NM; Countouriotis AM; Ruiz-Garcia A; Soria JC
Br J Cancer; 2010 Sep; 103(7):993-1000. PubMed ID: 20717111
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer.
Weiss GJ; Donehower RC; Iyengar T; Ramanathan RK; Lewandowski K; Westin E; Hurt K; Hynes SM; Anthony SP; McKane S
Invest New Drugs; 2013 Feb; 31(1):136-44. PubMed ID: 22492020
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer.
Tanai C; Yamamoto N; Ohe Y; Takahashi T; Kunitoh H; Murakami H; Yamamoto N; Nakamura Y; Nokihara H; Shukuya T; Baldwin JR; Koshiji M; Tamura T
J Thorac Oncol; 2010 Jul; 5(7):1068-74. PubMed ID: 20453691
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors.
Hanauske AR; Dumez H; Piccart M; Yilmaz E; Graefe T; Gil T; Simms L; Musib L; Awada A
Invest New Drugs; 2009 Aug; 27(4):356-65. PubMed ID: 18956139
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG
Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]